13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


Clinical trials : 3,342 Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCT2021200035
22/02/202124/12/2020Relapsing Forms of multiple sclerosis (RMS) study of Bruton's Tyrosine Kinase (BTK) inhibitor Tolebrutinib (SAR442168)A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio) in participants with relapsing forms of multiple sclerosis - GEMINI 1 Relapsing Multiple SclerosisDrug: SAR442168 (Tolebrutinib)
Pharmaceutical form: Tablet, Route of administration: Oral
Drug: Placebo to match SAR442168 (Tolebrutinib)
Pharmaceutical form: Tablet, Route of administration: Oral
Drug: Teriflunomide HMR1726
Pharmaceutical form: Tablet, Route of administration: Oral
Drug: Placebo to match Teriflunomide
Pharmaceutical form: Tablet, Route of administration: Oral
Tanaka TomoyukiNULLRecruiting>= 18age old<= 55age oldBoth900Phase 3Bulgaria;Canada;Czechia;Estonia;Spain;United States;Belarus;China;Finland;Germany;Italy;Lithuania;Poland;Romania;Russian Federation;Sweden;Taiwan;Turkey;Ukraine;Denmark;Japan
2NCT04410978
(ClinicalTrials.gov)
June 30, 202028/5/2020Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple SclerosisRelapsing Multiple SclerosisDrug: Tolebrutinib;Drug: Teriflunomide HMR1726;Drug: Placebo to match Tolebrutinib;Drug: Placebo to match TeriflunomideSanofiNULLRecruiting18 Years55 YearsAll900Phase 3United States;Austria;Belarus;Bulgaria;Canada;China;Czechia;Denmark;Estonia;Finland;Germany;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine
3NCT04410991
(ClinicalTrials.gov)
June 11, 202028/5/2020Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple SclerosisRelapsing Multiple SclerosisDrug: Tolebrutinib;Drug: Teriflunomide HMR1726;Drug: Placebo to match Tolebrutinib;Drug: Placebo to match TeriflunomideSanofiNULLRecruiting18 Years55 YearsAll900Phase 3United States;Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom
4NCT03856619
(ClinicalTrials.gov)
March 27, 201925/2/2019To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple SclerosisA Single Arm Phase IV Clinical Trial to Describe the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple SclerosisRelapsing Multiple SclerosisDrug: TERIFLUNOMIDE HMR1726SanofiNULLActive, not recruiting18 YearsN/AAll117Phase 4India
5NCT02046629
(ClinicalTrials.gov)
May 201423/1/2014A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese VolunteersAn Open-label, Single-dose Study to Evaluate the Pharmacokinetic Profiles of 14 mg Teriflunomide Tablet in Healthy Chinese SubjectsMultiple SclerosisDrug: Teriflunomide HMR1726;Drug: cholestyramineSanofiNULLCompleted18 Years45 YearsBoth12Phase 1China
6NCT01863888
(ClinicalTrials.gov)
October 201323/5/2013Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple SclerosisExploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple SclerosisMultiple SclerosisDrug: teriflunomide HMR1726;Drug: cholestyramine;Drug: charcoalSanofiNULLCompleted18 Years55 YearsBoth70Phase 3Belgium;Germany;Netherlands